dimethyl nandrolone undecanoate de testosterona

The use of salicylates in the I trimester of pregnancy leads to the development of splitting the upper palate, heart defects; in the III trimester causes inhibition of labor, dimethyl nandrolone undecanoate de testosterona premature closure of the ductus arteriosus in the fetus, increased bleeding in the mother and the fetus, and the appointment just before birth may cause intracranial hemorrhage, especially in preterm infants -. the use of salicylates in this trimester is contraindicated
in II trimester of pregnancy salicylates can prescribe only on the basis of strict risk assessment and benefit.

Use during lactation

Salicylates and their metabolites in small amounts into breast milk. Accidental intake of salicylates during lactation is not accompanied by the development of adverse reactions in children and does not require stopping breastfeeding. However, long-term use of the drug or to appoint him to a high dose of breast-feeding should be discontinued immediately.

Dosing and Administration

Tablets should be taken regardless of meals, not liquid, squeezed small amounts of water.

The drug is intended for long-term use. The dimethyl nandrolone undecanoate de testosterona duration of therapy is determined by the doctor.

Prophylaxis in cases of suspected acute myocardial infarction:
75 mg or 150 mg per day.

Prevention of new-onset acute myocardial infarction in the presence of risk factors:
75 mg or 150 mg per day.

Prophylaxis of recurrent myocardial infarction. Unstable angina. Prevention of stroke and transient ischemic attack. Prevention of thromboembolic complications of surgery or invasive investigations:
75 mg or 150 mg per day.

Prevention of deep vein thrombosis and pulmonary embolism and its branches:
75 mg or 150 mg per day.

Side effect

Gastrointestinal tract: nausea, heartburn, vomiting, pain in the abdomen, diarrhea, gastric mucosa and duodenal ulcers, including perforation, gastrointestinal bleeding, increased activity of “liver” enzymes.Respiratory system: bronchospasm. Central nervous system: vertigo, tinnitus. hemopoiesis system: increased bleeding, anemia (rare). Allergic reactions: urticaria, angioedema.

Overdose

The first symptoms of aspirin overdose are: nausea, vomiting, tinnitus, and shortness of breath.
There may also be symptoms such as hearing loss, visual disturbances, headache, motor excitation, drowsiness, seizures, hyperthermia. In severe intoxication may develop disturbance of acid-base and water-electrolyte balance (metabolic acidosis and dehydration).

Treatment :. There is no specific antidote
in case of an overdose of aspirin should:

 

  • cause vomiting and stomach wash (to reduce absorption of the drug). These actions give the effect 3-4 hours after administration, and in the case of receiving a very large doses – up to 10 hours;
  • ASA to reduce the absorption of activated carbon must be taken in the form of an aqueous suspension (dose for adults – 50-100 g, for children – 30-60 g);
  • you must carefully observe the violation of water-electrolyte balance and replenish it;
  • to accelerate excretion via the kidneys anddimethyl nandrolone undecanoate de testosterona in treating acidosis must enter intravenously sodium bicarbonate. It is necessary to maintain the pH in the range 7.0 – 7.5;
  • in very severe intoxication necessary to hemodialysis or peritoneal dialysis;
  • in connection with the development of respiratory acidosis it is forbidden to take drugs that suppress the central nervous system, such as barbiturates;
  • patients with respiratory failure is necessary to ensure airway patency and oxygen supply. If necessary, perform intratracheal intubation and to provide ventilation.

Interaction with other drugs

With simultaneous use of ASA enhances the effect of the following medicines:

 

  • methotrexate, due to reduction in renal clearance and displacement of its association with proteins;
  • heparin and indirect anticoagulants, due to dysfunction of platelets, and the displacement of anticoagulants due to the protein;
  • thrombolytic agents and platelet aggregation inhibitors (ticlopidine);
  • Digoxin, as a result of decrease in its renal excretion;
  • hypoglycemic agents (sulfonylureas and insulin) hypoglycemic properties by itself in high doses of and sulfonylurea derivatives of displacement due to the proteins;
  • valproic acid due to displacement of its association with proteins;
  • NSAIDs;
  • sulfanilmidov (including co-trimoxazole);
  • barbiturates;
  • lithium compounds.

An additive effect is observed while taking  with alcohol.

ASA reduces the effect of:

 

  • protivopodagricakih drugs that increase the excretion of uric acid (probenecid, sulfinpyrazone, benzbromaron), due to the competitive tubular elimination of uric acid;
  • antihypertensive agents including angiotensin-converting enzyme;
  • Aldosterone antagonists (e.g., spironolactone);
  • “Loop” diuretics (e.g., furosemide);

Leveraging the elimination of salicylates, systemic steroids weaken their effect.

special instructions

ASA may provoke bronchospasm and induce asthma attacks or other hypersensitivity reactions. Risk factors are the presence of a history of asthma, hay fever, nasal polyposis, chronic respiratory diseases and allergic reactions to other drugs (eg, skin reactions, pruritus, urticaria).

ASA can cause bleeding of varying severity during and after surgery. The drug should be discontinued for 5-7 days prior to the proposed transaction.

The combination of ASA with anticoagulants, thrombolytic drugs and inhibitors of platelet aggregation associated with an increased risk of bleeding. ASA in low doses can trigger the development of gout in susceptible individuals (with a reduced excretion of uric acid).

The combination of ASA with methotrexate is accompanied by an increased incidence of side effects of hematopoiesis.

High doses of ASA have a hypoglycemic effect, it must be borne in mind when assigning its patients with diabetes receiving hypoglycemic agents.

When combined appointment of glucocorticosteroids  and salicylates should be remembered that during treatment the level of salicylate in the blood is reduced, and after the abolition  possible overdose of salicylates.

ASA is not recommended to mix the ibuprofen, since it reduces the effectiveness of the drug dimethyl nandrolone undecanoate de testosteronaand thereby can reduce life expectancy.

Exceeding the dose ASA carries a risk of gastrointestinal bleeding.

With the combination of ASA and ethanol increased the risk of damage to the mucous membrane of the gastrointestinal tract and prolongation of bleeding time.

Overdose is especially dangerous in the elderly. Patients older than 65 years because of reduced kidney health and increased frequency of adverse reactions from the gastrointestinal tract should take  in smaller doses.

Effects on ability to focus and speed of psychomotor reactions

Data about the negative impact on the ability to control a car or work with no mechanisms.